232 related articles for article (PubMed ID: 27063622)
1. The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
Topping J; Dobson R; Lapin S; Maslyanskiy A; Kropshofer H; Leppert D; Giovannoni G; Evdoshenko E
Mult Scler Relat Disord; 2016 Mar; 6():49-53. PubMed ID: 27063622
[TBL] [Abstract][Full Text] [Related]
2. BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset.
Puthenparampil M; Federle L; Miante S; Zito A; Toffanin E; Ruggero S; Ermani M; Pravato S; Poggiali D; Perini P; Rinaldi F; Gallo P
J Neuroinflammation; 2017 Jan; 14(1):11. PubMed ID: 28095856
[TBL] [Abstract][Full Text] [Related]
3. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid.
Ragheb S; Li Y; Simon K; VanHaerents S; Galimberti D; De Riz M; Fenoglio C; Scarpini E; Lisak R
Mult Scler; 2011 Jul; 17(7):819-29. PubMed ID: 21372118
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of free light chains lambda and kappa in early multiple sclerosis.
Voortman MM; Stojakovic T; Pirpamer L; Jehna M; Langkammer C; Scharnagl H; Reindl M; Ropele S; Seifert-Held T; Archelos JJ; Fuchs S; Enzinger C; Fazekas F; Khalil M
Mult Scler; 2017 Oct; 23(11):1496-1505. PubMed ID: 27899552
[TBL] [Abstract][Full Text] [Related]
5. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
[TBL] [Abstract][Full Text] [Related]
6. Intrathecal K free light chain synthesis in multiple sclerosis at clinical onset associates with local IgG production and improves the diagnostic value of cerebrospinal fluid examination.
Puthenparampil M; Altinier S; Stropparo E; Zywicki S; Poggiali D; Cazzola C; Toffanin E; Ruggero S; Grassivaro F; Zaninotto M; Plebani M; Gallo P
Mult Scler Relat Disord; 2018 Oct; 25():241-245. PubMed ID: 30130707
[TBL] [Abstract][Full Text] [Related]
7. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement.
Bhargava P; Wicken C; Smith MD; Strowd RE; Cortese I; Reich DS; Calabresi PA; Mowry EM
Mult Scler Relat Disord; 2019 May; 30():136-140. PubMed ID: 30771580
[TBL] [Abstract][Full Text] [Related]
8. Elevated C-X-C motif ligand 13 and B-cell-activating factor levels in neuromyelitis optica during remission.
Wang S; Yang T; Wan J; Zhang Y; Fan Y
Brain Behav; 2017 Apr; 7(4):e00648. PubMed ID: 28413701
[TBL] [Abstract][Full Text] [Related]
9. Chemokine/cytokine profiling after rituximab: reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS.
Pranzatelli MR; Tate ED; Travelstead AL; Verhulst SJ
Cytokine; 2011 Mar; 53(3):384-9. PubMed ID: 21211990
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
[TBL] [Abstract][Full Text] [Related]
11. Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.
Lunde S; Kristoffersen EK; Sapkota D; Risa K; Dahl O; Bruland O; Mella O; Fluge Ø
PLoS One; 2016; 11(8):e0161226. PubMed ID: 27536947
[TBL] [Abstract][Full Text] [Related]
12. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
de Flon P; Gunnarsson M; Laurell K; Söderström L; Birgander R; Lindqvist T; Krauss W; Dring A; Bergman J; Sundström P; Svenningsson A
Neurology; 2016 Jul; 87(2):141-7. PubMed ID: 27316241
[TBL] [Abstract][Full Text] [Related]
13. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in relapsing-remitting multiple sclerosis.
De Palma R; Sementa A
N Engl J Med; 2008 Jun; 358(24):2645-6; author reply 2646-7. PubMed ID: 18550883
[No Abstract] [Full Text] [Related]
15. Effects of anti-CD20 therapy on circulating and intrathecal follicular helper T cell subsets in multiple sclerosis.
El Mahdaoui S; Hansen MM; Hansen MB; Hvalkof VH; Søndergaard HB; Mahler MR; Romme Christensen J; Sellebjerg F; von Essen MR
Clin Immunol; 2024 Jul; 264():110262. PubMed ID: 38788886
[TBL] [Abstract][Full Text] [Related]
16. BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy.
Pranzatelli MR; Tate ED; McGee NR; Travelstead AL; Colliver JA; Ness JM; Ransohoff RM
J Neuroinflammation; 2013 Jan; 10():10. PubMed ID: 23324534
[TBL] [Abstract][Full Text] [Related]
17. Association of cerebrospinal fluid kappa free light chains with the intrathecal polyspecific antiviral immune response in multiple sclerosis.
Huss A; Mojib-Yezdani F; Bachhuber F; Fangerau T; Lewerenz J; Otto M; Tumani H; Senel M
Clin Chim Acta; 2019 Nov; 498():148-153. PubMed ID: 31437445
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the efficacy and safety of Zytux
Naser Moghadasi A; Darki A; Masoumi P; Hashemi SN; Ghadiri F
Mult Scler Relat Disord; 2019 Nov; 36():101419. PubMed ID: 31586800
[TBL] [Abstract][Full Text] [Related]
19. Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study.
Bergman J; Burman J; Gilthorpe JD; Zetterberg H; Jiltsova E; Bergenheim T; Svenningsson A
Neurology; 2018 Nov; 91(20):e1893-e1901. PubMed ID: 30305449
[TBL] [Abstract][Full Text] [Related]
20. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Piccio L; Naismith RT; Trinkaus K; Klein RS; Parks BJ; Lyons JA; Cross AH
Arch Neurol; 2010 Jun; 67(6):707-14. PubMed ID: 20558389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
